Advertisement
Advertisement
BIIB
Biogen Inc. Common Stock
183.32
USDSponsored
-4.25
-2.27%
Mar 31, 15:59 UTC -4
Closed
After-Market
182.30
-1.01
-0.55%
BIIB Earnings Reports
Positive Surprise Ratio
BIIB beat 33 of 40 last estimates.
83%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$2.28B
/$3.12
Implied change from Q4 25 (Revenue/ EPS)
+0.23%
/+56.78%
Implied change from Q1 25 (Revenue/ EPS)
-6.02%
/+3.31%
Biogen Inc. Common Stock earnings per share and revenue
On Feb 06, 2026, BIIB reported earnings of 1.99 USD per share (EPS) for Q4 25, beating the estimate of 1.64 USD, resulting in a 20.87% surprise. Revenue reached 2.28 billion, compared to an expected 2.25 billion, with a 1.25% difference. The market reacted with a +8.53% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 17 analysts forecast an EPS of 3.12 USD, with revenue projected to reach 2.28 billion USD, implying an increase of 56.78% EPS, and increase of 0.23% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Palvella Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.92
Actual
-$1.08
Surprise
-16.19%
Bicara Therapeutics Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.68
Actual
-$0.68
Surprise
+0.66%
Neumora Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.33
Actual
-$0.35
Surprise
-5.39%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.17
Surprise
+7.41%
Sangamo Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-14.38%
RenovoRx, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
INmune Bio Inc. Common stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.18
Surprise
+32.13%
PDS Biotechnology Corporation Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.14
Surprise
+27.76%
VolitionRX Limited Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.05
Surprise
-17.65%
Lantern Pharma Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.36
Surprise
+23.27%
FAQ
What were Biogen Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Biogen Inc. Common Stock reported EPS of $1.99, beating estimates by 20.87%, and revenue of $2.28B, 1.25% above expectations.
How did the market react to Biogen Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 8.53%, changed from $185.36 before the earnings release to $201.18 the day after.
When is Biogen Inc. Common Stock expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for Biogen Inc. Common Stock's next earnings report?
Based on 17
analysts, Biogen Inc. Common Stock is expected to report EPS of $3.12 and revenue of $2.28B for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement